Apellis Pharmaceuticals, Inc. 8-K

What Happened
Apellis Pharmaceuticals (APLS) filed a Form 8-K on January 12, 2026, to announce that it issued a press release with preliminary unaudited U.S. net product revenue figures for SYFOVRE and EMPAVELI for the fourth quarter and full year ended December 31, 2025, and preliminary cash and cash equivalents as of December 31, 2025. The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Products reported: SYFOVRE and EMPAVELI — preliminary U.S. net product revenues for Q4 and full-year 2025 (amounts provided in the press release/exhibit).
• Cash position: Preliminary cash and cash equivalents reported as of December 31, 2025 (figure in press release).
• Status of figures: All amounts are preliminary, unaudited, management estimates subject to completion of the company’s financial close; the independent auditor has not audited or reviewed these numbers. The press release information is furnished, not “filed,” under Exchange Act Section 18 and is not incorporated by reference except where expressly stated.

Why It Matters
This notice gives investors an early look at Apellis’s recent revenue and cash position for Q4 and full-year 2025, which can affect near-term views on the company’s commercial performance for SYFOVRE and EMPAVELI. Because the figures are preliminary and unaudited, they may change when Apellis completes its financial close and files audited periodic reports; investors should rely on the final audited results in future SEC filings for definitive figures.